These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

599 related articles for article (PubMed ID: 10618600)

  • 41. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
    Bobba RS; Beattie K; Parkinson B; Kumbhare D; Adachi JD
    Drug Saf; 2006; 29(12):1133-52. PubMed ID: 17147460
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evolving role of bisphosphonates in women undergoing treatment for localized and advanced breast cancer.
    Gralow J
    Clin Breast Cancer; 2005 Feb; 5 Suppl(2):S54-62. PubMed ID: 15807925
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Double-blind, randomised, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease.
    Coleman RE; Purohit OP; Black C; Vinholes JJ; Schlosser K; Huss H; Quinn KJ; Kanis J
    Ann Oncol; 1999 Mar; 10(3):311-6. PubMed ID: 10355575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases.
    Berenson JR; Rosen LS; Howell A; Porter L; Coleman RE; Morley W; Dreicer R; Kuross SA; Lipton A; Seaman JJ
    Cancer; 2001 Apr; 91(7):1191-200. PubMed ID: 11283917
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bisphosphonate treatment of bone metastases and hypercalcemia of malignancy.
    Coleman RE
    Oncology (Williston Park); 1991 Aug; 5(8):55-60; discussion 60-2, 65. PubMed ID: 1834153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonates in the treatment of skeletal metastases.
    Conte P; Coleman R
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):59-63. PubMed ID: 15490377
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
    Aapro M; Saad F; Costa L
    Oncologist; 2010; 15(11):1147-58. PubMed ID: 21051658
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bisphosphonates for the relief of pain secondary to bone metastases.
    Wong R; Wiffen PJ
    Cochrane Database Syst Rev; 2002; 2002(2):CD002068. PubMed ID: 12076438
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM).
    Coleman RE
    Breast Cancer; 2000; 7(4):361-9. PubMed ID: 11114866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein MA; Coleman RE; Reitsma DJ; Chen BL; Seaman JJ
    Cancer; 2003 Oct; 98(8):1735-44. PubMed ID: 14534891
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of bisphosphonates in patients with metastatic bone disease.
    Berenson JR; Lipton A
    Oncology (Williston Park); 1998 Nov; 12(11):1573-9; discussion 1579-81. PubMed ID: 9834935
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of bisphosphonates in hormone-refractory prostate cancer.
    Saad F; Karakiewicz P; Perrotte P
    World J Urol; 2005 Feb; 23(1):14-8. PubMed ID: 15666171
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of dichloromethylene diphosphonate in metastatic bone disease.
    Jung A; Chantraine A; Donath A; van Ouwenaller C; Turnill D; Mermillod B; Kitler ME
    N Engl J Med; 1983 Jun; 308(25):1499-501. PubMed ID: 6222257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A double blind randomized study of oral clodronate in the treatment of bone metastases from tumors poorly responsive to chemotherapy.
    Piga A; Bracci R; Ferretti B; Sandri P; Nortilli R; Acito L; Pancotti A; Di Furia L; Carle F; Cellerino R
    J Exp Clin Cancer Res; 1998 Jun; 17(2):213-7. PubMed ID: 9700583
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toward new horizons: the future of bisphosphonate therapy.
    Lipton A
    Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bisphosphonates for malignancy-related bone disease: current status, future developments.
    Body JJ
    Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical efficacy and safety of zoledronic acid in prostate and breast cancer.
    Doggrell SA
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1211-8. PubMed ID: 19761424
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Zoledronic acid: a review of its use in patients with advanced cancer.
    Perry CM; Figgitt DP
    Drugs; 2004; 64(11):1197-211. PubMed ID: 15161327
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adjuvant bisphosphonate therapy: the future.
    Paterson AH
    Semin Oncol; 2001 Aug; 28(4 Suppl 11):81-5. PubMed ID: 11544582
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Management of bone metastases in breast cancer.
    Lipton A
    Curr Treat Options Oncol; 2005 Mar; 6(2):161-71. PubMed ID: 15717997
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.